Medicament therapy in the treatment of combined uterine diseases
Objective. Conduct a systematic analysis of the data available in the modern literature, with the purpose of assessing the effectiveness of drug treatment in patients with combined proliferative diseases of the uterus.Gasparyan S.A., Safonova O.A., Nalgieva M.I., Khripunova A.A.
Material and methods. The review includes data from domestic and foreign articles included in the PUBMED and RINC databases published over the past 10 years.
Results. The high prevalence of combined diseases of the uterus (leiomyomas, adenomyosis and endometrial hyperplasia) is described, including among women of working age. The treatment of these patients covers a wide range of conservative and surgical methods. The main goals of medical treatment of combined diseases of the uterus are: improving the quality of life, easing pain and bleeding, the possibility of avoiding a surgical operation and solving the problem of procreation. In order to optimize the correlation between the profiles of efficacy, safety and tolerability of treatment, it is possible to use the advantages of aHHRH (3-4 months) and dienogest (long-term) with their sequential appointment.
Conclusion. The development of an algorithm for the treatment with consecutive courses of drugs of various classes seems promising and requires further study.
Keywords
combined diseases of the uterus
gonadotropin-releasing hormone agonists
dienogest
myoma
endometriosis
endometrial hyperplasia
References
1. Lethaby A., Vollenhoven B., Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst. Rev. 2001; (2): CD000547.
2. Committee on Practice Bulletins-Gynecology. Practice bulletin no. 36: management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet. Gynecol. 2013; 122(1): 176-85.
3. Corona L.E., Swenson C.W., Sheetz K.H., Shelby G., Berger M.B., Pearlman M.D. et al. Use of other treatments before hysterectomy for benign conditions in a statewide hospital collaborative. Am. J. Obstet. Gynecol. 2015; 212(3): 304. e1-7.
4. Abu Hashim H., Ghayaty E., Rakhawy M. Levonorgestrel-releasing intrauterine system versus oral progestins for non-atypical endometrial hyperplasia: a systematic review and meta-analysis of randomized trials. Am. J. Obstet. Gynecol. 2015; 213(4): 469-78.
5. Strizhakov A.N., Davydov A.I. Endometriosis. Clinical and theoretical aspects. Moscow: Medicine; 1996. 330p. (in Russian)
6. Kumbak B., Oral E., Bukulmez O. Female obesity and assisted reproductive technologies. Semin. Reprod. Med. 2015; 30(6): 507-16.
7. Kovac S.R., Barhan S., Lister M., Tucker L., Bishop M., Das A. Guidelines for the selection of the route of hysterectomy: application in a resident clinic population. Am. J. Obstet. Gynecol. 2002; 187(6): 1521-7.
8. Bergholt T., Eriksen L., Berendt N., Jacobsen M., Hertz J.B. Prevalence and risk factors of adenomyosis at hysterectomy. Hum. Reprod. 2001; 16(11): 2418-21.
9. Guriev T.D., Sidorova I.S., Unanyan A.L. Combination of uterine fibroids and adenomyosis. A manual for doctors. Moscow: MIA; 2012. (in Russian)
10. Hamdan M., Omar S.Z., Dunselman G., Cheong Y. Influence of endometriosis on assisted reproductive technology outcomes: a systematic review and meta-analysis. Obstet. Gynecol. 2015; 125(1): 79-88.
11. Practice Committee of American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis. Fertil. Steril. 2008; 90(5 Suppl.): S260-9.
12. Jensen J.T., Hitt E. et al. Abnormal Menstrual Bleeding: New Definitions, New Strategies; NSAIDs May Treat Excessive Bleeding in Women With IUDs Drug & Reference Information American Society for Reproductive Medicine (ASRM). 65th Annual Meeting of the American Society for Reproductive Medicine. Atlanta, Georgia, October 18-21, 2009. Abstract O-107. Presented October 21, 2009.
13. Zhang Y., Sun L., Guo Y. et al. The impact of preoperative gonadotropin-releasing hormone agonist treatment on women with uterine fibroids: a meta-analysis. Obstet. Gynecol. Surv. 2014; 69: 100-8.
14. Kupker W. Paracrine changes in the peritoneal environment of women with endometriosis. Hum. Reprod. Update. 1998; 4(5): 719-23.
15. Kanelopulus N. Doppler-ultrasound as a predictor of uterine fibroid response to GnRH therapy. Int. J. Gynecol. Obstet. 2003; 82: 41-7.
16. Kang J.L., Wang X.X., Nie M.L., Huang X.H. Efficacy of gonadotropin-releasing hormone agonist and an extended-interval dosing regimen in the treatment of patients with adenomyosis and endometriosis. Gynecol. Obstet. Invest. 2010; 69(2): 73-7.
17. Кулаков В.И., Леонов Б.В., Корнеева И.Е., Смольникова В.Ю. Применение препарата аГнРГ диферелина в клинике бесплодия. Акушерство и гинекология. 2002; 4: 65-8. [Kulakov V.I., Leonov B.V., Korneeva I.E., Smolnikova V.Yu.
The use of the drug aHnRG dipherylin in the infertility clinic. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2002; (4): 65-8. (in Russian)]
18. Gerkulov D.A. The place of hormone therapy in overcoming infertility associated with severe forms of endometriosis. Zhurnal akusherstva i zhenskih bolezney. 2015; 64(5): 32-5. (in Russian)
19. Klinyshkova T.V., Perfilieva O.N. The effectiveness of treatment of patients with infertility and endometriosis of the ovaries. Ginekologiya. 2014; 6: 54-7. (in Russian)
20. Yakovleva N.V., Agadzanyan K.V. Combined method of treatment of patients with infertility associated with external genital endometriosis. In: Multidisciplinary Hospital: Problems and Solutions: Proceedings of the III All-Russian Scientific and Practical Conference (Leninsk-Kuznetsky, September 9-10, 2010). Novosibirsk; 2010: 246-7. (in Russian)
21. Krasnopolskaya K.V., Gorsky S.L., Mityushina N.G., Kabanova D.I. New approaches to increasing the effectiveness of IVF in endometriosis-associated infertility. Rossiyskiy vestnik akushera-ginekologa. 2009; 9(1): 53-6. (in Russian)
22. Davidson B., Abeler V.M., Førsund M., Holth A., Yang Y., Kobayashi Y. et al. Gene expression signatures of primary and metastatic uterine leiomyosarcoma. Hum. Pathol. 2014; 45(4): 691-700.
23. Dubuisson J.B., Charron C.H., Fauconnier A., Kreiker G. Laparoscopic myomectomy and myolysis. Curr. Opin. Obstet. Gynecol. 1997; 9(4): 233-8.
24. Di Nardo M.A. Pelvic adhesion and gonadotropin-releasing hormone analogue: effects of triptorelin acetate depot on coagulation and fibrinolytic activities. Reprod. Sci. 2012; 19(6): 615-22. doi: 10.1177/1933719111428517.
25. Ota Y., Andou M., Yanai S., Nakajima S., Fukuda M., Takano M. et al. Long-term administration of dienogest reduces recurrence after excision of endometrioma. J. Endometr. Pelvic Pain Disord. 2015; 7(2): 63-67
26. Petraglia F., Hornung D., Seitz C., Faustmann T., Gerlinger C.., Luisi S. et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch. Gynecol. Obstet. 2012; 285(1): 167-73.
27. Kitawaki J., Kusuki I., Yamanaka K., Suganuma I. Maintenance therapy with dienogest following gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011; 157(2) 212-6.
28. Sugimoto K., Nagata C., Hayashi H., Yanagida S., Okamoto A. Use of dienogest over 53weeks for the treatment of endometriosis. J. Obstet. Gynaecol. Res. 2015; 41(12): 1921-6.
29. Adachi K., Takahashi K., Nakamura K. et al. Postoperative administration of dienogest for suppressing recurrence of disease and relieving pain in subjects with ovarian endometriomas. Gynecol. Endocrinol. 2016; 32(8): 646-9.
30. Lee D.Y., Lee J.Y., Seo J.W., Yoon B.K., Choi D. Gonadotropin-releasing hormone agonist with add–back treatment is as effective and tolerable as dienogest in preventing pain recurrence after laparoscopic surgery for endometriosis. Arch. Gynecol. Obstet. 2016; 294(6): 1257-63.
31. Taran F.A., Weaver A.L., Coddington C.C. Characteristics indicating adenomyosis coexisting with leiomyomas: a case-control study. Hum. Reprod. 2010; 25(5): 1177-82.
32. Davis L., Kennedy S.S.., Moore J., Prentice A. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database Syst. Rev. 2007; (3): CD001019.
33. Al Kadri H., Hassan S., Al-Fozan H.M., Hajeer A. Hormone therapy for endometriosis and surgical menopause. Cochrane Database Syst. Rev. 2009; (1): CD005997.
34. Krasilnikov I.A., Mashkova I.V., Musiychuk Yu.I., Soldatenkova Zh.M. Manual for the Development of the International Statistical Classification of Diseases and Related Health Problems (tenth revision). For doctors and statisticians. St. Petersburg; 2008. (in Russian)
Received 16.06.2017
Accepted 23.06.2017
About the Authors
Gasparyan Susanna Artashesovna, MD, Professor, Department of Obstetrics and Gynecology, Stavropol State Medical University. 355017, Russia, Stavropol, Mira str. 310Safonova Olga Aleksandrovna, post-graduate student of the Department of Obstetrics and Gynecology, Stavropol State Medical University.
355017, Russia, Stavropol, Mira str. 310
Nalgiyeva Marina Ilesovna, head of the gynecological department of the Ingush Republican Clinical Hospital. 386101, Republic of Ingushetia, Nazran, Mutalieva str. 11
Khripunova Alesya Alexandrovna, Ph.D., Associate Professor, Department of Public Health, Public Health Service and Medical Informatics, Stavropol State Medical University. 355017, Russia, Stavropol, Mira str. 310
For citations: Gasparyan S.A., Safonova O.A., Nalgieva M.I., Khripunova A.A. Medicament therapy in the treatment of combined uterine diseases. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (7): 150-4. (in Russian)
http://dx.doi.org/10.18565/aig.2017.7.150-4
Similar Articles
